دورية أكاديمية
أعرض في EDS

Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.

التفاصيل البيبلوغرافية
العنوان: Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
المؤلفون: Flosdorf N; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany., Böhnke J; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany., de Toledo MAS; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Lutterbach N; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany., Lerma VG; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany., Graßhoff M; Institute of Computational Genomics, RWTH Aachen University Hospital, Aachen, Germany., Olschok K; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Gupta S; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Tharmapalan V; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Institute for Stem Cell Biology, RWTH Aachen University Medical School, Aachen, Germany., Schmitz S; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany., Götz K; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany., Schüler HM; Institute for Human Genetics and Genome Medicine, Faculty of Medicine, RWTH Aachen University, Aachen, Germany; Center for Rare Diseases, Medical Faculty, and University Hospital Düsseldorf Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany., Maurer A; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Sontag S; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany., Küstermann C; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany., Seré K; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany., Wagner W; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Institute for Stem Cell Biology, RWTH Aachen University Medical School, Aachen, Germany., Costa IG; Institute of Computational Genomics, RWTH Aachen University Hospital, Aachen, Germany., Brümmendorf TH; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Koschmieder S; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Chatain N; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany., Castilho M; Eindhoven University of Technology, Eindhoven, the Netherlands., Schneider RK; Institute for Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany., Zenke M; Department of Cell Biology, Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany; Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany. Electronic address: martin.zenke@rwth-aachen.de.
المصدر: Stem cell reports [Stem Cell Reports] 2024 Feb 13; Vol. 19 (2), pp. 224-238. Date of Electronic Publication: 2024 Jan 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101611300 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-6711 (Electronic) Linking ISSN: 22136711 NLM ISO Abbreviation: Stem Cell Reports Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, c 2013-
مواضيع طبية MeSH: Induced Pluripotent Stem Cells* , Polycythemia Vera*/genetics , Polycythemia Vera*/pathology, Humans ; Mice ; Animals ; Bone Marrow/pathology ; Megakaryocytes ; Janus Kinase 2/genetics ; Phenotype ; Fibrosis ; Mutation
مستخلص: The myeloproliferative disease polycythemia vera (PV) driven by the JAK2 V617F mutation can transform into myelofibrosis (post-PV-MF). It remains an open question how JAK2 V617F in hematopoietic stem cells induces MF. Megakaryocytes are major players in murine PV models but are difficult to study in the human setting. We generated induced pluripotent stem cells (iPSCs) from JAK2 V617F PV patients and differentiated them into megakaryocytes. In differentiation assays, JAK2 V617F iPSCs recapitulated the pathognomonic skewed megakaryocytic and erythroid differentiation. JAK2 V617F iPSCs had a TPO-independent and increased propensity to differentiate into megakaryocytes. RNA sequencing of JAK2 V617F iPSC-derived megakaryocytes reflected a proinflammatory, profibrotic phenotype and decreased ribosome biogenesis. In three-dimensional (3D) coculture, JAK2 V617F megakaryocytes induced a profibrotic phenotype through direct cell contact, which was reversed by the JAK2 inhibitor ruxolitinib. The 3D coculture system opens the perspective for further disease modeling and drug discovery.
Competing Interests: Declaration of interests W.W. and V.T. are involved in Cygenia GmbH (www.cygenia.com), which provides services for DNA methylation analysis to other scientists. S.K. reports funding from Novartis, Bristol-Myers Squibb, and Janssen/Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, GSK, Sierra Oncology, and Sanofi; a patent for Bromodomain and Extra-Terminal (BET) inhibitor at RWTH Aachen University; honoraria from Novartis, Bristol Myers Squibb, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, and AOP Pharma; and other financial support (e.g., travel support) from Alexion, Novartis, Bristol Myers Squibb, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Imago Biosciences, Sierra Oncology, GSK, and Karthos. T.H.B. served as a consultant for Janssen, Merck, Novartis, and Pfizer; received research funding form Novartis and Pfizer; and received honoraria from Janssen, Merck, Novartis, and Pfizer.
(Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5688-E5695. (PMID: 29866839)
Sci Transl Med. 2022 Oct 12;14(666):eabm6391. (PMID: 36223446)
Blood Adv. 2022 Feb 22;6(4):1222-1231. (PMID: 35051996)
Stem Cells Transl Med. 2015 Apr;4(4):309-19. (PMID: 25713465)
Genome Biol. 2016 May 03;17:83. (PMID: 27142433)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Hematol Oncol. 2018 Mar 15;11(1):42. (PMID: 29544547)
N Engl J Med. 2005 Apr 28;352(17):1779-90. (PMID: 15858187)
Nature. 2005 Apr 28;434(7037):1144-8. (PMID: 15793561)
Cancer Discov. 2023 Feb 6;13(2):364-385. (PMID: 36351055)
Blood. 2023 Apr 20;141(16):1909-1921. (PMID: 36347013)
Blood. 2014 May 15;123(20):3139-51. (PMID: 24692758)
Development. 2017 Jul 1;144(13):2323-2337. (PMID: 28676567)
Sci Adv. 2022 Feb 18;8(7):eabj8618. (PMID: 35171685)
Sci Rep. 2018 Jan 19;8(1):1245. (PMID: 29352189)
Blood. 2008 Sep 15;112(6):2190-8. (PMID: 18779404)
Front Cell Dev Biol. 2021 Jul 22;9:667304. (PMID: 34368123)
Sci Rep. 2021 Mar 4;11(1):5255. (PMID: 33664283)
Blood. 2017 Mar 23;129(12):1607-1616. (PMID: 28159736)
Exp Hematol. 2014 Sep;42(9):816-25. (PMID: 24859480)
Exp Hematol. 2019 Mar;71:77-84. (PMID: 30481543)
Blood. 2018 May 10;131(19):2111-2119. (PMID: 29572380)
Hemasphere. 2020 May 21;4(3):e371. (PMID: 32647796)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Expert Rev Hematol. 2018 Mar;11(3):169-184. (PMID: 29400094)
Blood. 2020 Oct 29;136(18):2051-2064. (PMID: 32726410)
Blood. 2011 Dec 8;118(24):6392-8. (PMID: 21860020)
Cancer Cell. 2018 Jan 8;33(1):29-43.e7. (PMID: 29249691)
Genome Res. 2019 Aug;29(8):1363-1375. (PMID: 31340985)
Nat Biotechnol. 2014 Jun;32(6):554-61. (PMID: 24837661)
Nat Commun. 2022 May 24;13(1):2885. (PMID: 35610203)
J Hematol Oncol. 2017 Sep 29;10(1):156. (PMID: 28962635)
Front Oncol. 2022 Mar 22;12:853484. (PMID: 35392239)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Blood. 2021 Apr 15;137(15):2070-2084. (PMID: 33512435)
Stem Cells. 2017 Apr;35(4):898-908. (PMID: 28090699)
Cell Stem Cell. 2020 Oct 1;27(4):523-531. (PMID: 33007237)
Stem Cell Reports. 2018 Dec 11;11(6):1462-1478. (PMID: 30503262)
Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254)
Nat Commun. 2018 Jan 2;9(1):20. (PMID: 29295995)
N Engl J Med. 2018 Oct 11;379(15):1416-1430. (PMID: 30304655)
Stem Cell Reports. 2021 Nov 9;16(11):2768-2783. (PMID: 34678208)
Blood. 2017 Feb 9;129(6):667-679. (PMID: 28028029)
Nat Med. 2016 Mar;22(3):288-97. (PMID: 26878232)
Stem Cell Res. 2021 Aug;55:102490. (PMID: 34391098)
Leukemia. 2020 Apr;34(4):1062-1074. (PMID: 31728053)
Cell Rep. 2023 Feb 28;42(2):112131. (PMID: 36807143)
PLoS One. 2013 Sep 16;8(9):e74257. (PMID: 24066127)
PLoS One. 2011;6(6):e21015. (PMID: 21698292)
Stem Cells. 2014 Jan;32(1):269-78. (PMID: 24105986)
Exp Hematol. 2023 Feb;118:12-20. (PMID: 36511286)
Am J Hematol. 2011 Apr;86(4):343-5. (PMID: 21442636)
Am J Hematol. 2021 Jan;96(1):145-162. (PMID: 33197049)
Mol Cell. 2020 May 7;78(3):477-492.e8. (PMID: 32386542)
Acta Biomater. 2019 Sep 1;95:297-306. (PMID: 31233890)
Blood. 2014 Dec 18;124(26):3956-63. (PMID: 25339357)
EMBO Mol Med. 2015 Jul 14;7(11):1388-402. (PMID: 26174486)
Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8. (PMID: 33301706)
المشرفين على المادة: EC 2.7.10.2 (Janus Kinase 2)
EC 2.7.10.2 (JAK2 protein, human)
تواريخ الأحداث: Date Created: 20240126 Date Completed: 20240216 Latest Revision: 20240221
رمز التحديث: 20240221
مُعرف محوري في PubMed: PMC10874863
DOI: 10.1016/j.stemcr.2023.12.011
PMID: 38278152
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-6711
DOI:10.1016/j.stemcr.2023.12.011